Raftopoulou Christina, Roumelioti Fani-Marlen, Dragona Eleni, Gimelli Stefanie, Sloan-Béna Frédérique, Gorgoulis Vasilis, Antonarakis Stylianos E, Gagos Sarantis
Laboratory of Genetics, Center of Experimental Medicine and Translational Research, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece (BRFAA).
Department of Genetic Medicine and Development, University of Geneva Medical School, 1211 Geneva, Switzerland.
Cancers (Basel). 2020 Mar 5;12(3):591. doi: 10.3390/cancers12030591.
Ongoing chromosomal instability in neoplasia (CIN) generates intratumor genomic heterogeneity and limits the efficiency of oncotherapeutics. Neoplastic human cells utilizing the alternative lengthening of telomeres (ALT)-pathway, display extensive structural and numerical CIN. To unravel patterns of genome evolution driven by oncogene-replication stress, telomere dysfunction, or genotoxic therapeutic interventions, we examined by comparative genomic hybridization five karyotypically-diverse outcomes of the ALT osteosarcoma cell line U2-OS. These results demonstrate a high tendency of the complex cancer genome to perpetuate specific genomic imbalances despite the karyotypic evolution, indicating an ongoing process of genome dosage maintenance. Molecular karyotyping in four ALT human cell lines showed that mitotic cells with low levels of random structural CIN display frequent evidence of whole genome doubling (WGD), suggesting that WGD may protect clonal chromosome aberrations from hypermutation. We tested this longstanding hypothesis in ALT cells exposed to gamma irradiation or to inducible DNA replication stress under overexpression of p21. Single-cell cytogenomic analyses revealed that although polyploidization promotes genomic heterogeneity, it also protects the complex cancer genome and hence confers genotoxic therapy resistance by generating identical extra copies of driver chromosomal aberrations, which can be spared in the process of tumor evolution if they undergo unstable or unfit rearrangements.
肿瘤中持续存在的染色体不稳定性(CIN)会产生肿瘤内基因组异质性,并限制肿瘤治疗的效率。利用端粒替代延长(ALT)途径的肿瘤人类细胞表现出广泛的结构和数量CIN。为了揭示由癌基因复制应激、端粒功能障碍或基因毒性治疗干预驱动的基因组进化模式,我们通过比较基因组杂交研究了ALT骨肉瘤细胞系U2-OS的五种核型不同的结果。这些结果表明,尽管核型发生了进化,但复杂的癌症基因组仍有很高的倾向使特定的基因组失衡持续存在,这表明基因组剂量维持是一个持续的过程。对四种ALT人类细胞系进行的分子核型分析表明,随机结构CIN水平较低的有丝分裂细胞经常出现全基因组加倍(WGD)的迹象,这表明WGD可能保护克隆染色体畸变免于超突变。我们在暴露于γ射线或在p21过表达情况下受到诱导性DNA复制应激的ALT细胞中检验了这一长期存在的假设。单细胞细胞基因组分析表明,虽然多倍体化会促进基因组异质性,但它也能保护复杂的癌症基因组,从而通过产生驱动染色体畸变的相同额外拷贝赋予对基因毒性治疗的抗性,如果这些额外拷贝经历不稳定或不合适的重排,它们在肿瘤进化过程中可以被保留下来。